Notably, pan-RAS inhibition alters the immunological composition of the tumor microenvironment, as illustrated in Figure 3, by enhancing the infiltration of CD4+ and CD8+ T cells and raising the quantity of MHC class II-positive tumor cells. The gene discussed is CD4; the disease is neoplasm.